110PEvaluation of pathological complete response as a trial-level surrogate for long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant therapy. (13th May 2019) - Huang, M; Qi, C Z; Ramsey, S; Briggs, A; Zhao, J; Haiderali, A; Karantza, V; Xie, J; Gu, C; Fasching, P A